A developer of transdermal drug delivery treatments for pain and central nervous systems diseases has been awarded a Medicines Manufacturing Grant by Innovate UK.
Grant
Medherant was awarded the £52,000 grant to help it buy equipment and prepare for the manufacture of patches formulated with TEPI patch technology for clinical trials.
The company’s TEPI patch technology enables manufacturers to produce transdermal patches containing doses of active ingredients. The technology is designed to provide better adhesion and more efficient delivery of drugs through the skin over a longer period.
Recently, Medherant put its Ibuprofen TEPI patch through Phase I clinical development and is expecting the initial results sometime in 2018.
The company has also recently installed its own pilot-scale patch manufacturing plant where it has successfully produced non-GMP versions of its Ibuprofen TEPI patch.